Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials

Nutrition

Volumn 31, Issue 7-8, 2015, Pages 923-930

  Sato, Ken ^a   Gosho, Masahiko ^a   Yamamoto, Takaya ^a   Kobayashi, Yuji ^a   Ishii, Norimitsu ^a   Ohashi, Tomohiko ^a   Nakade, Yukiomi ^a   Ito, Kiyoaki ^a   Fukuzawa, Yoshitaka ^a   Yoneda, Masashi ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Meta analysis; NAFLD; NASH; Nonalcoholic steatohepatitis; Vitamin E; Tocopherol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID; ANTIOXIDANT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HUMAN; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DRUG EFFECTS; ENZYMOLOGY; FATTY LIVER; FIBROSIS; INFLAMMATION; LIVER; LIVER CELL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FIBROSIS; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAMIN E;

EID: 84945957859     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.11.018     Document Type: Article

References (45)

1. Marignani M., Angeletti S. Nonalcoholic fatty liver disease. New Engl J Med 2002, 347:768-769.
2. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease. Ann Epidemiol 2007, 17:863-869.
3. Brunt E.M., Kleiner D.E., Wilson L.A., Belt P., Neuschwander-Tetri B.A. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 2011, 53:810-820.
4. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
5. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 y. Hepatology 1990, 11:74-80.
6. Day C.P., James O.F. Steatohepatitis: A tale of two "hits"?. Gastroenterology 1998, 114:842-845.
7. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
8. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002, 16:663-678.
9. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012, 61:141-152.
10. Parola M., Muraca R., Dianzani I., Barrera G., Lenoarduzzi G., Bendinelli P., et al. Vitamin E dietary supplementation transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992, 308:267-270.
11. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001, 15:1667-1672.
12. Lirussi F., Azzalini L., Orlando S., Orlando R., Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, CD004996.
13. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
14. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. Pharmacologic interventions for nonalcoholic fatty liver disease in adults and in children: A systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
15. Ji H.F., Sun Y., Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: Results from a meta-analysis. Nutrition 2014, 30:986-991.
16. Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
17. Boettcher E., Csako G., Pucino F., Wesley R., Loomba R. Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012, 35:66-75.
18. Du J., Ma Y.Y., Yu C.H., Li Y.M. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014, 20:569-577.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
21. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010, 362:1675-1685.
23. Wang C.L., Liang L., Fu J.F., Zou C.C., Hong F., Xue J.Z., et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008, 14:1598-1602.
24. Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
25. Vajro P., Mandato C., Franzese A., Ciccimarra E., Lucariello S., Savoia M., et al. Vitamin E treatment in pediatric obesity-related liver disease: A randomized study. J Pediatr Gastroenterol Nutr 2004, 38:48-55.
26. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
27. Fan J.G., Li F., Cai X.B., Peng Y.D., Ao Q.H., Gao Y. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 2007, 22:663-668.
28. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
29. Wang Z., Xia B., Ma C., Hu Z., Chen X., Cao P. Prevalence and risk factors of fatty liver disease in the Shuiguohu district of Wuhan city, central China. Postgrad Med J 2007, 83:192-195.
30. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
31. Hashimoto E., Tokushige K., Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res 2015, 45:20-28.
32. Chalasani N., Deeg M.A., Crabb D.W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1497-1502.
33. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37:56-62.
34. Harrison S.A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-2490.
35. Nobili V., Manco M., Devito R., Di Ciommo V., Comparcola D., Sartorelli M.R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48:119-128.
36. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
37. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012, 107:811-826.
38. The Japanese Society of Gastroenterology. Available at:. http://www.jsge.or.jp/member/oshirase/topics/new4_disease_guideline.html.
39. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
40. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007, 297:842-857.
41. Berry D., Wathen J.K., Newell M. Bayesian model averaging in meta-analysis: Vitamin E supplementation and mortality. Clinical Trials 2009, 6:28-41.
42. Gerss J., Kopcke W. The questionable association of vitamin E supplementation and mortality-inconsistent results of different meta-analytical approaches. Cell Mol Biol (Noisy-le-grand) 2009, (55 Suppl):OL1111-OL1120.
43. Dietrich M., Jacques P.F., Pencina M.J., Lanier K., Keyes M.J., Kaur G., et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?. Atherosclerosis 2009, 205:549-553.
44. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306:1549-1556.
45. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.